person · Reporting owner

PAPA JOSEPH C

Disclosed activity across 6 companies

Tapewire entity: 33888
SEC CIK: 0001242215

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Bausch & Lomb CorpBLCO · Entity 3756	Director · CEO & Chairman	May 05, 2022	May 09, 2022
Bausch Health Companies Inc.BHC · Entity 4363	Director	May 10, 2022	May 13, 2022
Candel Therapeutics, Inc.CADL · Entity 4969	Director	September 30, 2026	October 02, 2026
Emergent BioSolutions Inc.EBS · Entity 5902	Director · President and CEO	April 29, 2026	May 01, 2026
Milestone Pharmaceuticals Inc.MIST · Entity 6561	Director	June 10, 2026	June 12, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Bausch & Lomb Corp

Report date May 05, 2022 · Filed May 09, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Shares, No Par ValueSEC Table I · non-derivative	Direct	472,222	Reported balance After 2022-05-05 transaction · row 1 1 source row Row 1 · 2022-05-05 · Grant · Acquired 472,222 · Balance 472,222 F1: Reflects the grant of restricted stock units ("RSUs") under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the "Plan"). Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch + Lomb Corporation.
Non-Qualified Stock Options (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00	Direct	1,868,131	Reported balance After 2022-05-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-05-05 · Grant · Acquired 1,868,131 · Balance 1,868,131 F2: Reflects the grant of stock options to purchase Common Shares under the Plan. F3: The stock options are generally scheduled to vest and become exercisable in equal installments on each of the first three anniversaries of the grant date, subject to the terms of the applicable award agreement. F4: The stock options will expire on the tenth anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the grant of restricted stock units ("RSUs") under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the "Plan"). Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch + Lomb Corporation.

F2: Reflects the grant of stock options to purchase Common Shares under the Plan.

F3: The stock options are generally scheduled to vest and become exercisable in equal installments on each of the first three anniversaries of the grant date, subject to the terms of the applicable award agreement.

F4: The stock options will expire on the tenth anniversary of the grant date.

Bausch Health Companies Inc.

Report date May 10, 2022 · Filed May 13, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Shares, No Par ValueSEC Table I · non-derivative	Direct	1,427,568	Ending reported balance After 2022-05-10 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2022-05-10 · Exercise / conversion · Acquired 116,697 · Balance 1,211,849 F1: Reflects an award of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person on February 26, 2020, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on February 26, 2023, subject to the reporting person's continuous service. F4: Each PSU converts into Common Shares on a one-for-one basis. Row 2 · 2022-05-10 · Exercise / conversion · Acquired 183,522 · Balance 1,395,371 F2: Reflects an award of PSUs, previously granted to the reporting person on March 3, 2021, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on March 3, 2023, subject to the reporting person's continuous service. F4: Each PSU converts into Common Shares on a one-for-one basis. Row 3 · 2022-05-10 · Exercise / conversion · Acquired 65,911 · Balance 1,461,282 F3: Reflects the vesting and conversion of certain "Separation PSUs", previously granted to the reporting person on March 3, 2021, into common shares, no par value ("Common Shares") of the Issuer. F4: Each PSU converts into Common Shares on a one-for-one basis. Row 4 · 2022-05-10 · Tax withholding · Disposed 33,714 · Balance 1,427,568 F5: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of the reporting person's Separation PSUs.
Restricted Share UnitsSEC Table II · derivative / convertible security · Expires 2022-05-10	Direct	0	Reported balance After 2022-05-10 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-05-10 · Grant · Acquired 116,697 · Balance 0 F4: Each PSU converts into Common Shares on a one-for-one basis. F1: Reflects an award of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person on February 26, 2020, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on February 26, 2023, subject to the reporting person's continuous service.
Restricted Share UnitsSEC Table II · derivative / convertible security · Expires 2022-05-10	Direct	0	Reported balance After 2022-05-10 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-05-10 · Exercise / conversion · Disposed 116,697 · Balance 0 F4: Each PSU converts into Common Shares on a one-for-one basis. F1: Reflects an award of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person on February 26, 2020, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on February 26, 2023, subject to the reporting person's continuous service.
Restricted Share UnitsSEC Table II · derivative / convertible security · Expires 2022-05-10	Direct	0	Reported balance After 2022-05-10 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-05-10 · Grant · Acquired 183,522 · Balance 0 F4: Each PSU converts into Common Shares on a one-for-one basis. F2: Reflects an award of PSUs, previously granted to the reporting person on March 3, 2021, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on March 3, 2023, subject to the reporting person's continuous service.
Restricted Share UnitsSEC Table II · derivative / convertible security · Expires 2022-05-10	Direct	0	Reported balance After 2022-05-10 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-05-10 · Exercise / conversion · Disposed 183,522 · Balance 0 F4: Each PSU converts into Common Shares on a one-for-one basis. F2: Reflects an award of PSUs, previously granted to the reporting person on March 3, 2021, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on March 3, 2023, subject to the reporting person's continuous service.
Restricted Share UnitsSEC Table II · derivative / convertible security · Expires 2022-05-10	Direct	0	Reported balance After 2022-05-10 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-05-10 · Grant · Acquired 65,911 · Balance 0 F4: Each PSU converts into Common Shares on a one-for-one basis. F3: Reflects the vesting and conversion of certain "Separation PSUs", previously granted to the reporting person on March 3, 2021, into common shares, no par value ("Common Shares") of the Issuer.
Restricted Share UnitsSEC Table II · derivative / convertible security · Expires 2022-05-10	Direct	0	Reported balance After 2022-05-10 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2022-05-10 · Exercise / conversion · Disposed 65,911 · Balance 0 F4: Each PSU converts into Common Shares on a one-for-one basis. F3: Reflects the vesting and conversion of certain "Separation PSUs", previously granted to the reporting person on March 3, 2021, into common shares, no par value ("Common Shares") of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects an award of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person on February 26, 2020, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on February 26, 2023, subject to the reporting person's continuous service.

F2: Reflects an award of PSUs, previously granted to the reporting person on March 3, 2021, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on March 3, 2023, subject to the reporting person's continuous service.

F3: Reflects the vesting and conversion of certain "Separation PSUs", previously granted to the reporting person on March 3, 2021, into common shares, no par value ("Common Shares") of the Issuer.

F4: Each PSU converts into Common Shares on a one-for-one basis.

F5: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of the reporting person's Separation PSUs.

Candel Therapeutics, Inc.

Report date September 30, 2026 · Filed October 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.44 · Expires 2036-09-30	Direct	1,325	Reported balance After 2026-09-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-09-30 · Grant · Acquired 1,325 · Balance 1,325 F1: This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant.

Filing footnotes · ownership attribution and instrument terms

F1: This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant.

Emergent BioSolutions Inc.

Report date April 29, 2026 · Filed May 01, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	493,153	Reported balance After 2026-04-29 transaction · row 1 1 source row Row 1 · 2026-04-29 · Grant · Acquired 187,708 · Balance 493,153 F1: The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026. F2: Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

Filing footnotes · ownership attribution and instrument terms

F1: The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.

F2: Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

Milestone Pharmaceuticals Inc.

Report date June 10, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2036-06-10	Direct	77,000	Reported balance After 2026-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-10 · Grant · Acquired 77,000 · Balance 77,000 F1: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Prometheus Biosciences, Inc.

Report date June 16, 2023 · Filed June 16, 2023

Section 16 reporting ended · disclosed 2023-06-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-06-16 transaction · row 1 1 source row Row 1 · 2023-06-16 · Disposition to issuer · Disposed 7,278 · Balance 0 F1: Includes 2,278 restricted stock units. F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option.
Common StockSEC Table I · non-derivative	IndirectBy The Papa Family Charitable Trust	Reported balance After 2023-06-16 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2023-06-16 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. F4: The Reporting Person is a Trustee to The Papa Family Charitable Trust.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.10 · Expires 2030-08-24	Direct	Reported balance After 2023-06-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-06-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.70 · Expires 2030-12-17	Direct	Reported balance After 2023-06-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-06-16 · Disposition to issuer · Disposed 27,340 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.70 · Expires 2031-02-03	Direct	Reported balance After 2023-06-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-06-16 · Disposition to issuer · Disposed 22,652 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.32 · Expires 2031-11-13	Direct	Reported balance After 2023-06-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-06-16 · Disposition to issuer · Disposed 2,165 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.02 · Expires 2032-05-18	Direct	Reported balance After 2023-06-16 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-06-16 · Disposition to issuer · Disposed 22,551 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 2,278 restricted stock units.

F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3)

F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option.

F4: The Reporting Person is a Trustee to The Papa Family Charitable Trust.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 30, 2026 Filed Oct 2, 2026 21:56 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	GrantStock Option (Right to Buy) · Derivative	1,325	$8.68 Strike: $10.44	$11,495.70	Disclosure SEC source: 0001193125-26-412655 · ownership.xml · derivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,325 Underlying: Common Stock · 1,325 shares Expires 2036-09-30 F1 · derivative.exercise_date: This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant. Read SEC document
June 30, 2026 Filed Jul 1, 2026 20:20 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	GrantStock Option (Right to Buy) · Derivative	1,331	$8.64 Strike: $10.30	$11,498.51	Disclosure SEC source: 0001242215-26-000018 · ownership.xml · derivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,331 Underlying: Common Stock · 1,331 shares Expires 2036-06-30 F1 · derivative.exercise_date: This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant. Read SEC document
June 23, 2026 Filed Jun 24, 2026 20:33 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	GrantStock Option (Right to Buy) · Derivative	32,000	$0.00 Strike: $9.08	$0.00	Disclosure SEC source: 0001242215-26-000016 · ownership.xml · derivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document
June 10, 2026 Filed Jun 12, 2026 20:15 UTC	Milestone Pharmaceuticals Inc. MIST · Entity 6561	GrantStock Option (right to buy) · Derivative	77,000	$0.00 Strike: $1.22	$0.00	Disclosure SEC source: 0001242215-26-000014 · form4-06122026_040609.xml · derivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document
April 29, 2026 Filed May 1, 2026 20:26 UTC	Emergent BioSolutions Inc. EBS · Entity 5902	GrantCommon Stock	187,708	$0.00	$0.00	Disclosure SEC source: 0001242215-26-000012 · wk-form4_1777667176.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 493,153 F1 · deemedExecutionDate: The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026. F2 · shares: Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document
March 31, 2026 Filed Apr 2, 2026 21:10 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	GrantStock Option (Right to Buy) · Derivative	2,795	$4.11 Strike: $4.90	$11,498.63	Disclosure SEC source: 0001242215-26-000010 · ownership.xml · derivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,795 Underlying: Common Stock · 2,795 shares Expires 2036-03-31 F1 · derivative.exercise_date: This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant. Read SEC document
March 05, 2026 Filed Mar 6, 2026 02:40 UTC	Emergent BioSolutions Inc. EBS · Entity 5902	Tax withholdingCommon Stock	37,055	$8.44	$312,744.20	Disclosure SEC source: 0001242215-26-000008 · wk-form4_1772764826.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 305,445 F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of performance stock units. Read SEC document
March 03, 2026 Filed Mar 6, 2026 02:40 UTC	Emergent BioSolutions Inc. EBS · Entity 5902	GrantEmployee Stock Option (Right to buy) · Derivative	252,194	$0.00 Strike: $8.99	$0.00	Disclosure SEC source: 0001242215-26-000008 · wk-form4_1772764826.xml · derivative · entry 2 PAPA JOSEPH C · CIK 0001242215 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,784,694 Underlying: Common Stock · 252,194 shares Expires 2033-03-02 F2 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document
July 11, 2025 Filed Jul 15, 2025 20:15 UTC	Milestone Pharmaceuticals Inc. MIST · Entity 6561	GrantSeries B Common Warrants (right to buy) · Derivative	100,000	Not disclosed Strike: $1.88	Not disclosed	Disclosure SEC source: 0001415889-25-019770 · form4-07152025_040701.xml · derivative · entry 3 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2030-07-11 F1 · price: The reported securities are included within 100,000 Issuer Units purchased by the Reporting Person for $1.50 per Unit. Each Unit consists of one common share, one Series A common warrant and one Series B common warrant, each warrant represents the right to purchase 100,000 shares of common stock. F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document
July 11, 2025 Filed Jul 15, 2025 20:15 UTC	Milestone Pharmaceuticals Inc. MIST · Entity 6561	GrantSeries A Common Warrants (right to buy) · Derivative	100,000	Not disclosed Strike: $1.50	Not disclosed	Disclosure SEC source: 0001415889-25-019770 · form4-07152025_040701.xml · derivative · entry 2 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2026-07-11 F1 · price: The reported securities are included within 100,000 Issuer Units purchased by the Reporting Person for $1.50 per Unit. Each Unit consists of one common share, one Series A common warrant and one Series B common warrant, each warrant represents the right to purchase 100,000 shares of common stock. F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document
July 11, 2025 Filed Jul 15, 2025 20:15 UTC	Milestone Pharmaceuticals Inc. MIST · Entity 6561	GrantCommon Shares	100,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-019770 · form4-07152025_040701.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 F1 · price: The reported securities are included within 100,000 Issuer Units purchased by the Reporting Person for $1.50 per Unit. Each Unit consists of one common share, one Series A common warrant and one Series B common warrant, each warrant represents the right to purchase 100,000 shares of common stock. Read SEC document
June 25, 2025 Filed Jun 26, 2025 12:30 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	GrantCommon Stock	64,239	$4.67	$299,996.13	Disclosure SEC source: 0000950170-25-090191 · ownership.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Joseph C. Papa Revocable Living Trust Disclosed balance after: 64,239 F1 · kind: Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025. F2 · ownership.nature: Shares held by Joseph C. Papa Revocable Living Trust, which is wholly owned by a trust for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any. Read SEC document
June 17, 2025 Filed Jun 18, 2025 12:32 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	GrantStock Option (Right to Buy) · Derivative	14,240	$0.00 Strike: $4.94	$0.00	Disclosure SEC source: 0000950170-25-087697 · ownership.xml · derivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 14,240 shares Expires 2035-06-17 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 17, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document
June 10, 2025 Filed Jun 12, 2025 20:19 UTC	Milestone Pharmaceuticals Inc. MIST · Entity 6561	GrantStock Option (right to buy) · Derivative	40,000	$0.00 Strike: $1.75	$0.00	Disclosure SEC source: 0001415889-25-016932 · form4-06122025_040611.xml · derivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2025, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document
May 13, 2025 Filed May 15, 2025 20:02 UTC	Emergent BioSolutions Inc. EBS · Entity 5902	PurchaseCommon Stock	60,000	$5.83	$349,800.00	Disclosure SEC source: 0001367644-25-000127 · wk-form4_1747339349.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 342,500 F1 · price: On May 13, 2025, Mr. Papa purchased an aggregate of 60,000 shares of Emergent BioSolutions Inc. common stock. For reporting purposes, purchase prices within a $1 range have been aggregated and the weighted average purchase price has been reported. The price ranges were: $5.76 - $5.88. The Company maintains a record of the transactions and copies will be provided upon request. Read SEC document
March 12, 2025 Filed Mar 12, 2025 22:12 UTC	Emergent BioSolutions Inc. EBS · Entity 5902	GrantEmployee Stock Options (Right to Buy) · Derivative	250,000	$0.00 Strike: $2.33	$0.00	Disclosure SEC source: 0001367644-25-000058 · wk-form4_1741817572.xml · derivative · entry 2 PAPA JOSEPH C · CIK 0001242215 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,532,500 Underlying: Common Stock · 250,000 shares Expires 2031-03-12 F1 · shares: Consists of an award of performance stock options granted under the company's Inducement Plan. These performance stock options vested in one annual installment on the day prior to the first anniversary of the date of grant based on the achievement of the $5 and $10 stock price performance hurdles as described in Mr. Papa's executive employment agreement dated February 19, 2024 (the "Papa Employment Agreement") and as certified by the company's Compensation Committee on February 12, 2025. Pursuant to the award, there remains 250,000 unvested performance stock options that are subject to a $15 stock price performance hurdle as described in the Papa Employment Agreement. Each performance stock option represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc. at the exercise price. Read SEC document
March 12, 2025 Filed Mar 12, 2025 22:12 UTC	Emergent BioSolutions Inc. EBS · Entity 5902	GrantEmployee Stock Options (Right to Buy) · Derivative	250,000	$0.00 Strike: $2.33	$0.00	Disclosure SEC source: 0001367644-25-000058 · wk-form4_1741817572.xml · derivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,282,500 Underlying: Common Stock · 250,000 shares Expires 2031-03-12 F1 · shares: Consists of an award of performance stock options granted under the company's Inducement Plan. These performance stock options vested in one annual installment on the day prior to the first anniversary of the date of grant based on the achievement of the $5 and $10 stock price performance hurdles as described in Mr. Papa's executive employment agreement dated February 19, 2024 (the "Papa Employment Agreement") and as certified by the company's Compensation Committee on February 12, 2025. Pursuant to the award, there remains 250,000 unvested performance stock options that are subject to a $15 stock price performance hurdle as described in the Papa Employment Agreement. Each performance stock option represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc. at the exercise price. Read SEC document
March 06, 2025 Filed Mar 10, 2025 20:17 UTC	Emergent BioSolutions Inc. EBS · Entity 5902	GrantEmployee Stock Options (Right to Buy) · Derivative	282,500	$0.00 Strike: $5.80	$0.00	Disclosure SEC source: 0001367644-25-000048 · wk-form4_1741637843.xml · derivative · entry 2 PAPA JOSEPH C · CIK 0001242215 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,032,500 Underlying: Common Stock · 282,500 shares Expires 2032-03-05 F2 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document
March 06, 2025 Filed Mar 10, 2025 20:17 UTC	Emergent BioSolutions Inc. EBS · Entity 5902	GrantCommon Stock	282,500	$0.00	$0.00	Disclosure SEC source: 0001367644-25-000048 · wk-form4_1741637843.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 282,500 F1 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each performance stock unit represents a right to receive one share of common stock. The performance stock units vest in three annual installments beginning on the day prior to the anniversary of the date of grant, assuming continued service with the company and upon achievement with respect to Adjusted EBITDA for the 2025 fiscal year, as certified by the Compensation Committee following the performance period. Read SEC document
September 03, 2024 Filed Sep 5, 2024 20:31 UTC	Milestone Pharmaceuticals Inc. MIST · Entity 6561	GrantStock Option (right to buy) · Derivative	80,000	$0.00 Strike: $1.39	$0.00	Disclosure SEC source: 0001415889-24-022914 · form4-09052024_080906.xml · derivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Shares · 80,000 shares Expires 2034-09-03 F1 · derivative.exercise_date: This option will vest in equal monthly installments, beginning on October 3, 2024, over a period of three years, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document
June 26, 2024 Filed Jun 27, 2024 12:41 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	GrantStock Option (Right to Buy) · Derivative	14,240	$0.00 Strike: $5.71	$0.00	Disclosure SEC source: 0000950170-24-078175 · ownership.xml · derivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 14,240 shares Expires 2034-06-26 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 26, 2025 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document
March 13, 2024 Filed Mar 15, 2024 21:16 UTC	Emergent BioSolutions Inc. EBS · Entity 5902	GrantEmployee Stock Options (Right to Buy) · Derivative	750,000	$0.00 Strike: $2.33	$0.00	Disclosure SEC source: 0001367644-24-000045 · wk-form4_1710537389.xml · derivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2031-03-12 F1 · shares: Consists of 500,000 options to purchase shares granted under the Emergent BioSolutions Inc. Amended and Restated Stock Incentive Plan and 250,000 options to purchase shares granted under the Emergent BioSolutions Inc. Inducement Plan. F2 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document
June 28, 2023 Filed Jun 29, 2023 13:00 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	GrantStock Option (Right to Buy) · Derivative	14,240	$0.00 Strike: $1.22	$0.00	Disclosure SEC source: 0001209191-23-040132 · doc4.xml · derivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 14,240 shares Expires 2033-06-28 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 28, 2024 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document
June 16, 2023 Filed Jun 16, 2023 20:00 UTC	Prometheus Biosciences, Inc. RXDX · Entity 112175	Disposition to issuerStock Option (right to buy) · Derivative	22,551	Not disclosed Strike: $29.02	Not disclosed	Disclosure SEC source: 0000899243-23-015759 · doc4.xml · derivative · entry 7 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,551 shares Expires 2032-05-18 F2 · price: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3 · price: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3 · derivative.exercise_date: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. Read SEC document
June 16, 2023 Filed Jun 16, 2023 20:00 UTC	Prometheus Biosciences, Inc. RXDX · Entity 112175	Disposition to issuerStock Option (right to buy) · Derivative	2,165	Not disclosed Strike: $36.32	Not disclosed	Disclosure SEC source: 0000899243-23-015759 · doc4.xml · derivative · entry 6 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,165 shares Expires 2031-11-13 F2 · price: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3 · price: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3 · derivative.exercise_date: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. Read SEC document
June 16, 2023 Filed Jun 16, 2023 20:00 UTC	Prometheus Biosciences, Inc. RXDX · Entity 112175	Disposition to issuerStock Option (right to buy) · Derivative	22,652	Not disclosed Strike: $6.70	Not disclosed	Disclosure SEC source: 0000899243-23-015759 · doc4.xml · derivative · entry 5 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,652 shares Expires 2031-02-03 F2 · price: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3 · price: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3 · derivative.exercise_date: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. Read SEC document
June 16, 2023 Filed Jun 16, 2023 20:00 UTC	Prometheus Biosciences, Inc. RXDX · Entity 112175	Disposition to issuerStock Option (right to buy) · Derivative	27,340	Not disclosed Strike: $3.70	Not disclosed	Disclosure SEC source: 0000899243-23-015759 · doc4.xml · derivative · entry 4 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,340 shares Expires 2030-12-17 F2 · price: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3 · price: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3 · derivative.exercise_date: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. Read SEC document
June 16, 2023 Filed Jun 16, 2023 20:00 UTC	Prometheus Biosciences, Inc. RXDX · Entity 112175	Disposition to issuerStock Option (right to buy) · Derivative	15,000	Not disclosed Strike: $3.10	Not disclosed	Disclosure SEC source: 0000899243-23-015759 · doc4.xml · derivative · entry 3 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2030-08-24 F2 · price: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3 · price: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3 · derivative.exercise_date: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. Read SEC document
June 16, 2023 Filed Jun 16, 2023 20:00 UTC	Prometheus Biosciences, Inc. RXDX · Entity 112175	Disposition to issuerCommon Stock	10,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-23-015759 · doc4.xml · nonDerivative · entry 2 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Papa Family Charitable Trust Disclosed balance after: 0 F2 · price: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3 · price: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. F4 · ownership.nature: The Reporting Person is a Trustee to The Papa Family Charitable Trust. Read SEC document
June 16, 2023 Filed Jun 16, 2023 20:00 UTC	Prometheus Biosciences, Inc. RXDX · Entity 112175	Disposition to issuerCommon Stock	7,278	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-23-015759 · doc4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 2,278 restricted stock units. F2 · price: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3) F3 · price: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. Read SEC document
June 02, 2023 Filed Jun 2, 2023 22:43 UTC	Prometheus Biosciences, Inc. RXDX · Entity 112175	OtherCommon Stock	10,000	$0.00	$0.00	Disclosure SEC source: 0001209191-23-034004 · doc4.xml · nonDerivative · entry 2 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Papa Family Charitable Trust Disclosed balance after: 10,000 F1 · kind: Transfer of shares from the Reporting Person to The Papa Family Charitable Trust. F2 · ownership.nature: The Reporting Person is a Trustee to The Papa Family Charitable Trust. Read SEC document
June 02, 2023 Filed Jun 2, 2023 22:43 UTC	Prometheus Biosciences, Inc. RXDX · Entity 112175	OtherCommon Stock	10,000	$0.00	$0.00	Disclosure SEC source: 0001209191-23-034004 · doc4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,278 F1 · kind: Transfer of shares from the Reporting Person to The Papa Family Charitable Trust. Read SEC document
May 19, 2023 Filed May 19, 2023 21:44 UTC	Prometheus Biosciences, Inc. RXDX · Entity 112175	GrantCommon Stock	2,278	$0.00	$0.00	Disclosure SEC source: 0001209191-23-031188 · doc4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,278 F1 · kind: Award of restricted stock units ("RSUs") granted under the Issuer's 2021 Incentive Award Plan (the "2021 Plan"). Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting. The RSUs shall vest in full upon the earlier to occur of (i) the first anniversary of the date of grant, (ii) the Issuer's next occurring annual meeting of stockholders, or (iii) a Change of Control (as defined in the 2021 Plan), subject to the Reporting Person's continued service with the Issuer on such vesting date. Read SEC document
December 09, 2022 Filed Dec 12, 2022 21:25 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	PurchaseCommon Stock	35,018	$1.94	$67,934.92	Disclosure SEC source: 0001209191-22-060694 · doc4.xml · nonDerivative · entry 2 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,032 F2 · price: The price in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.85 to $2.00. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
December 08, 2022 Filed Dec 12, 2022 21:25 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	PurchaseCommon Stock	3,014	$1.70	$5,123.80	Disclosure SEC source: 0001209191-22-060694 · doc4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,014 F1 · price: The price in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.55 to $1.80. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
August 08, 2022 Filed Aug 10, 2022 12:05 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	GrantStock Option (Right to Buy) · Derivative	28,480	$0.00 Strike: $3.38	$0.00	Disclosure SEC source: 0000899243-22-028201 · doc4.xml · derivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,480 Underlying: Common Stock · 28,480 shares Expires 2032-08-08 F1 · derivative.exercise_date: 33% of the shares underlying this option shall vest and become exercisable on August 8, 2023, with the remainder vesting in two (2) equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document
May 19, 2022 Filed May 20, 2022 23:26 UTC	Prometheus Biosciences, Inc. RXDX · Entity 112175	GrantStock Option (Right to Buy) · Derivative	22,551	$0.00 Strike: $29.02	$0.00	Disclosure SEC source: 0001209191-22-031176 · doc4.xml · derivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,551 Underlying: Common Stock · 22,551 shares Expires 2032-05-18 F1 · derivative.exercise_date: The shares subject to the option will vest in full upon the earlier to occur of (i) the first anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date. Read SEC document
May 10, 2022 Filed May 13, 2022 01:12 UTC	Bausch Health Companies Inc. BHC · Entity 4363	Exercise / conversionRestricted Share Units · Derivative	65,911	$9.40	$619,563.40	Disclosure SEC source: 0000899243-22-017885 · doc4.xml · derivative · entry 10 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 0 shares Expires 2022-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis. F3 · shares: Reflects the vesting and conversion of certain "Separation PSUs", previously granted to the reporting person on March 3, 2021, into common shares, no par value ("Common Shares") of the Issuer. F3 · derivative.exercise_date: Reflects the vesting and conversion of certain "Separation PSUs", previously granted to the reporting person on March 3, 2021, into common shares, no par value ("Common Shares") of the Issuer. Read SEC document
May 10, 2022 Filed May 13, 2022 01:12 UTC	Bausch Health Companies Inc. BHC · Entity 4363	GrantRestricted Share Units · Derivative	65,911	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-017885 · doc4.xml · derivative · entry 9 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 65,911 shares Expires 2022-05-10 F4 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis. F3 · shares: Reflects the vesting and conversion of certain "Separation PSUs", previously granted to the reporting person on March 3, 2021, into common shares, no par value ("Common Shares") of the Issuer. F4 · price: Each PSU converts into Common Shares on a one-for-one basis. F3 · derivative.exercise_date: Reflects the vesting and conversion of certain "Separation PSUs", previously granted to the reporting person on March 3, 2021, into common shares, no par value ("Common Shares") of the Issuer. Read SEC document
May 10, 2022 Filed May 13, 2022 01:12 UTC	Bausch Health Companies Inc. BHC · Entity 4363	Exercise / conversionRestricted Share Units · Derivative	183,522	$9.40	$1,725,106.80	Disclosure SEC source: 0000899243-22-017885 · doc4.xml · derivative · entry 8 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 0 shares Expires 2022-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis. F2 · shares: Reflects an award of PSUs, previously granted to the reporting person on March 3, 2021, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on March 3, 2023, subject to the reporting person's continuous service. F2 · derivative.exercise_date: Reflects an award of PSUs, previously granted to the reporting person on March 3, 2021, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on March 3, 2023, subject to the reporting person's continuous service. Read SEC document
May 10, 2022 Filed May 13, 2022 01:12 UTC	Bausch Health Companies Inc. BHC · Entity 4363	GrantRestricted Share Units · Derivative	183,522	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-017885 · doc4.xml · derivative · entry 7 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 183,522 shares Expires 2022-05-10 F4 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis. F2 · shares: Reflects an award of PSUs, previously granted to the reporting person on March 3, 2021, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on March 3, 2023, subject to the reporting person's continuous service. F4 · price: Each PSU converts into Common Shares on a one-for-one basis. F2 · derivative.exercise_date: Reflects an award of PSUs, previously granted to the reporting person on March 3, 2021, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on March 3, 2023, subject to the reporting person's continuous service. Read SEC document
May 10, 2022 Filed May 13, 2022 01:12 UTC	Bausch Health Companies Inc. BHC · Entity 4363	Exercise / conversionRestricted Share Units · Derivative	116,697	$9.40	$1,096,951.80	Disclosure SEC source: 0000899243-22-017885 · doc4.xml · derivative · entry 6 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 0 shares Expires 2022-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis. F1 · shares: Reflects an award of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person on February 26, 2020, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on February 26, 2023, subject to the reporting person's continuous service. F1 · derivative.exercise_date: Reflects an award of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person on February 26, 2020, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on February 26, 2023, subject to the reporting person's continuous service. Read SEC document
May 10, 2022 Filed May 13, 2022 01:12 UTC	Bausch Health Companies Inc. BHC · Entity 4363	GrantRestricted Share Units · Derivative	116,697	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-017885 · doc4.xml · derivative · entry 5 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 116,697 shares Expires 2022-05-10 F4 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis. F1 · shares: Reflects an award of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person on February 26, 2020, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on February 26, 2023, subject to the reporting person's continuous service. F4 · price: Each PSU converts into Common Shares on a one-for-one basis. F1 · derivative.exercise_date: Reflects an award of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person on February 26, 2020, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on February 26, 2023, subject to the reporting person's continuous service. Read SEC document
May 10, 2022 Filed May 13, 2022 01:12 UTC	Bausch Health Companies Inc. BHC · Entity 4363	Tax withholdingCommon Shares, No Par Value	33,714	$9.40	$316,911.60	Disclosure SEC source: 0000899243-22-017885 · doc4.xml · nonDerivative · entry 4 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,427,568 F5 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of the reporting person's Separation PSUs. Read SEC document
May 10, 2022 Filed May 13, 2022 01:12 UTC	Bausch Health Companies Inc. BHC · Entity 4363	Exercise / conversionCommon Shares, No Par Value	65,911	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-017885 · doc4.xml · nonDerivative · entry 3 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,461,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Reflects the vesting and conversion of certain "Separation PSUs", previously granted to the reporting person on March 3, 2021, into common shares, no par value ("Common Shares") of the Issuer. F4 · price: Each PSU converts into Common Shares on a one-for-one basis. Read SEC document
May 10, 2022 Filed May 13, 2022 01:12 UTC	Bausch Health Companies Inc. BHC · Entity 4363	Exercise / conversionCommon Shares, No Par Value	183,522	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-017885 · doc4.xml · nonDerivative · entry 2 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,395,371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Reflects an award of PSUs, previously granted to the reporting person on March 3, 2021, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on March 3, 2023, subject to the reporting person's continuous service. F4 · price: Each PSU converts into Common Shares on a one-for-one basis. Read SEC document
May 10, 2022 Filed May 13, 2022 01:12 UTC	Bausch Health Companies Inc. BHC · Entity 4363	Exercise / conversionCommon Shares, No Par Value	116,697	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-017885 · doc4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,211,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects an award of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person on February 26, 2020, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on February 26, 2023, subject to the reporting person's continuous service. F4 · price: Each PSU converts into Common Shares on a one-for-one basis. Read SEC document
May 05, 2022 Filed May 9, 2022 22:45 UTC	Bausch & Lomb Corp BLCO · Entity 3756	GrantNon-Qualified Stock Options (right to purchase) · Derivative	1,868,131	$0.00 Strike: $18.00	$0.00	Disclosure SEC source: 0000899243-22-017320 · doc4.xml · derivative · entry 2 PAPA JOSEPH C · CIK 0001242215 · Director · CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,868,131 Underlying: Common Shares, No Par Value · 1,868,131 shares Expires not disclosed F2 · shares: Reflects the grant of stock options to purchase Common Shares under the Plan. F3 · derivative.exercise_date: The stock options are generally scheduled to vest and become exercisable in equal installments on each of the first three anniversaries of the grant date, subject to the terms of the applicable award agreement. F4 · derivative.expiration_date: The stock options will expire on the tenth anniversary of the grant date. Read SEC document
May 05, 2022 Filed May 9, 2022 22:45 UTC	Bausch & Lomb Corp BLCO · Entity 3756	GrantCommon Shares, No Par Value	472,222	$0.00	$0.00	Disclosure SEC source: 0000899243-22-017320 · doc4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · CEO & Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,222 F1 · shares: Reflects the grant of restricted stock units ("RSUs") under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the "Plan"). Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch + Lomb Corporation. Read SEC document
March 03, 2022 Filed Mar 7, 2022 22:34 UTC	Bausch Health Companies Inc. BHC · Entity 4363	Tax withholdingCommon Shares, No Par Value	12,643	$23.61	$298,501.23	Disclosure SEC source: 0001127602-22-008488 · form4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,095,152 F1 · shares: This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.